Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement

Salazar, Carlos; Málaga, Germán; Malasquez, Giuliana

doi:10.1002/14651858.cd005981.pub2

Cited by 34 publications

(31 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of minor bleeding was 1.4% (58 events), while serious bleeding occurred in only one patient. This value was much lower than that (12.3%) for patients who underwent total hip or knee replacement while receiving low-molecular-weight heparin or vitamin K antagonists 14 . Unfortunately, the review 13 did not include the retrospective review discussed here, although the results are consistent and the sample size in this review was relatively large.…”

Section: Commentarymentioning

confidence: 79%

Does acupuncture increase the risk of bleeding in patients taking warfarin?

Leem

2015

Integrative Medicine Research

View full text Add to dashboard Cite

Section: Commentarymentioning

confidence: 79%

Does acupuncture increase the risk of bleeding in patients taking warfarin?

Leem

2015

Integrative Medicine Research

View full text Add to dashboard Cite

“…In this group, thrombin inhibitors were superior to enoxaparin in the prevention of venous thromboembolism. Ximelagatran was extensively studied as thromboprophylaxis in patients subjected to total knee surgery, with favourable results versus warfarin [48][49][50][51][52][53].…”

Section: Ximelagatran In Venous Thromboembolismmentioning

confidence: 99%

Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants

Deftereos

Hatzis²,

Kossyvakis³

et al. 2012

CCP

View full text Add to dashboard Cite

Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism, is the third most common cause of vascular death after myocardial infarction and stroke. Clinicians are often summoned to make challenging decisions for the prevention and treatment of high risk patients with an unpredicted outcome, often relying on data that are less than definitive. During the last decades, heparins (unfractionated and low molecular weight heparins) as well as vitamin K antagonists, such as warfarin, and indirect Xa inhibitors, such as fontaparinux, are the cornerstone for the prevention and treatment of patients with venous thromboembolism. However, the traditionally used anticoagulants have several drawbacks that may limit their efficacy and use in every day clinical practise. The newly developed oral anticoagulants, belonging to the categories of direct thrombin inhibitors (DTIs) and direct Xa inhibitors, have emerged as promising agents with remarkable efficacy, concentrating many parameters of an ideal anticoagulant. Rivaroxaban, dabigatran and apixaban are the most studied agents, while a plethora of others are investigated in clinical trials of different phases and are expected to reach the market in the following years. The purpose of this review is to summarize the so far acquired knowledge on these agents, to report briefly some of their pharmacodynamic and pharmacokinetic properties and to focus on their role in the treatment and prevention of venous thromboembolism.

show abstract

“…33 Four studies including 10183 patients were included (BISTRO II, REMOBILIZE, RENOVATE and REMODEL). Results were reported in combination with all other direct thrombin inhibitors.…”

Section: Clinical Trials Prophylaxis Of Venous Thromboembolismmentioning

confidence: 99%

Prevention and Treatment of Venous Thromboembolic Events: Focus on Dabigatran Etexilate

Cheng

2011

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

This article reviews the pharmacology and clinical evidence of the use of dabigatran etexilate (DE) in the prevention and treatment of venous thromboembolism (VTE). Published data in English language were identified from MEDLINE and Current Content database (1966 to January 30, 2011) using the search terms dabigatran, VTE, deep vein thrombosis, and pulmonary embolism. Citations from available articles were reviewed for additional references. DE is an oral direct thrombin inhibitor that has a rapid onset of action, achieving peak anticoagulation effect in 0.5-2 hours. In clinical studies, DE has demonstrated superiority and non-inferiority to enoxaparin for VTE prophylaxis and non-inferiority to warfarin for VTE treatment. A common side effect of DE is gastrointestinal complaints. The overall rates of major bleeding were low, and minor bleeding was commonly noted but similar in incidence to other anticoagulant (enoxaparin and warfarin). Future studies should focus on long-term efficacy and safety compared to other anticoagulants, and for other clinical indications.

show abstract

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement

Abstract: Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.

Cited by 34 publications

References 75 publications

Does acupuncture increase the risk of bleeding in patients taking warfarin?

Does acupuncture increase the risk of bleeding in patients taking warfarin?

Prevention and Treatment of Venous Thromboembolism and Pulmonary Embolism: The Role of Novel Oral Anticoagulants

Prevention and Treatment of Venous Thromboembolic Events: Focus on Dabigatran Etexilate

Contact Info

Product

Resources

About